Build Your Comparison

Side-by-side financial analysis
NAKA logo
NAKA
HIMS logo
HIMS
TDOC logo
TDOC
OPRX logo
OPRX
AMWL logo
AMWL
Try popular comparisons:

Stock Comparison

NAKA vs HIMS vs TDOC vs OPRX vs AMWL

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NAKA
Nakamoto Inc.

Financial - Capital Markets

Financial ServicesNASDAQ • US
Market Cap$79M
5Y Perf.-96.3%
HIMS
Hims & Hers Health, Inc.

Medical - Equipment & Services

HealthcareNYSE • US
Market Cap$6.62B
5Y Perf.+55.4%
TDOC
Teladoc Health, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$1.35B
5Y Perf.-33.6%
OPRX
OptimizeRx Corporation

Medical - Healthcare Information Services

HealthcareNASDAQ • US
Market Cap$100M
5Y Perf.-55.9%
AMWL
American Well Corporation

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$145M
5Y Perf.+1.8%

NAKA vs HIMS vs TDOC vs OPRX vs AMWL — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NAKA logoNAKA
HIMS logoHIMS
TDOC logoTDOC
OPRX logoOPRX
AMWL logoAMWL
IndustryFinancial - Capital MarketsMedical - Equipment & ServicesMedical - Healthcare Information ServicesMedical - Healthcare Information ServicesMedical - Healthcare Information Services
Market Cap$79M$6.62B$1.35B$100M$145M
Revenue (TTM)$4M$2.37B$2.51B$107M$182M
Net Income (TTM)$-290M$-13M$-171M$7M$-88M
Gross Margin-376.0%67.6%65.6%69.0%38.7%
Operating Margin-82.2%1.3%-7.6%13.6%-50.6%
Forward P/E59.2x5.6x
Total Debt$210M$1.26B$1.04B$26M$5M
Cash & Equiv.$23M$229M$781M$23M$182M

NAKA vs HIMS vs TDOC vs OPRX vs AMWLLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NAKA
HIMS
TDOC
OPRX
AMWL
StockMay 24Jun 26Return
Nakamoto Inc. (NAKA)1003.7-96.3%
Hims & Hers Health,… (HIMS)100155.4+55.4%
Teladoc Health, Inc. (TDOC)10066.4-33.6%
OptimizeRx Corporat… (OPRX)10044.1-55.9%
American Well Corpo… (AMWL)100101.8+1.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: NAKA vs HIMS vs TDOC vs OPRX vs AMWL

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: OPRX leads in 3 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. American Well Corporation is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. HIMS also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇OPRX emerged as the overall leader. Track its performance:
NAKA
Nakamoto Inc.
The Financial Services Pick

NAKA lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: financial services exposure
HIMS
Hims & Hers Health, Inc.
The Long-Run Compounder

HIMS ranks third and is worth considering specifically for long-term compounding.

  • 207.9% 10Y total return vs OPRX's 56.9%
  • 59.0% revenue growth vs NAKA's -33.0%
Best for: long-term compounding
TDOC
Teladoc Health, Inc.
The Healthcare Pick

Among these 5 stocks, TDOC doesn't own a clear edge in any measured category.

Best for: healthcare exposure
OPRX
OptimizeRx Corporation
The Income Pick

OPRX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 1 yrs, beta 2.18
  • Rev growth 18.8%, EPS growth 124.5%, 3Y rev CAGR 20.6%
  • Better valuation composite
  • 6.4% margin vs NAKA's -74.0%
Best for: income & stability and growth exposure
AMWL
American Well Corporation
The Defensive Pick

AMWL is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.

  • Lower volatility, beta 1.45, Low D/E 1.8%, current ratio 3.37x
  • Beta 1.45, current ratio 3.37x
  • Beta 1.45 vs NAKA's 2.88, lower leverage
  • +25.4% vs NAKA's -99.3%
Best for: sleep-well-at-night and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthHIMS logoHIMS59.0% revenue growth vs NAKA's -33.0%
ValueOPRX logoOPRXBetter valuation composite
Quality / MarginsOPRX logoOPRX6.4% margin vs NAKA's -74.0%
Stability / SafetyAMWL logoAMWLBeta 1.45 vs NAKA's 2.88, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)AMWL logoAMWL+25.4% vs NAKA's -99.3%
Efficiency (ROA)OPRX logoOPRX4.0% ROA vs NAKA's -56.5%, ROIC 6.8% vs -42.1%

NAKA vs HIMS vs TDOC vs OPRX vs AMWL — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the GLP-1 Stocks Theme

These companies are key players in the GLP-1 Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
NAKANakamoto Inc.
FY 2025
Product Retail Sales
100.0%$1,479
HIMSHims & Hers Health, Inc.

Segment breakdown not available.

TDOCTeladoc Health, Inc.
FY 2025
Other
100.0%$438M
OPRXOptimizeRx Corporation
FY 2025
Other Revenue
100.0%$215,000
AMWLAmerican Well Corporation
FY 2025
Platform Subscription
53.1%$132M
Visits
37.8%$94M
Others
9.1%$23M

NAKA vs HIMS vs TDOC vs OPRX vs AMWL — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLOPRXLAGGINGNAKA

Income & Cash Flow (Last 12 Months)

OPRX leads this category, winning 5 of 6 comparable metrics.

TDOC is the larger business by revenue, generating $2.5B annually — 641.5x NAKA's $4M. OPRX is the more profitable business, keeping 6.4% of every revenue dollar as net income compared to NAKA's -74.0%. On growth, NAKA holds the edge at +3.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNAKA logoNAKANakamoto Inc.HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…AMWL logoAMWLAmerican Well Cor…
RevenueTrailing 12 months$4M$2.4B$2.5B$107M$182M
EBITDAEarnings before interest/tax-$320M$99M$42M$19M-$59M
Net IncomeAfter-tax profit-$290M-$13M-$171M$7M-$88M
Free Cash FlowCash after capex-$46M$76M$251M$14M-$42M
Gross MarginGross profit ÷ Revenue-3.8%+67.6%+65.6%+69.0%+38.7%
Operating MarginEBIT ÷ Revenue-82.2%+1.3%-7.6%+13.6%-50.6%
Net MarginNet income ÷ Revenue-74.0%-0.6%-6.8%+6.4%-48.2%
FCF MarginFCF ÷ Revenue-11.7%+3.2%+10.0%+13.4%-22.9%
Rev. Growth (YoY)Latest quarter vs prior year+3.6%+3.8%-2.5%-9.5%-100.0%
EPS Growth (YoY)Latest quarter vs prior year-88.4%-3.0%+32.1%+78.0%+44.5%
OPRX leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

TDOC leads this category, winning 3 of 5 comparable metrics.

At 19.7x trailing earnings, OPRX trades at a 67% valuation discount to HIMS's 59.2x P/E. On an enterprise value basis, OPRX's 6.3x EV/EBITDA is more attractive than HIMS's 47.8x.

MetricNAKA logoNAKANakamoto Inc.HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…AMWL logoAMWLAmerican Well Cor…
Market CapShares × price$79M$6.6B$1.3B$100M$145M
Enterprise ValueMkt cap + debt − cash$266M$7.7B$1.6B$103M-$33M
Trailing P/EPrice ÷ TTM EPS-0.43x59.16x-6.54x19.70x-1.46x
Forward P/EPrice ÷ next-FY EPS est.5.65x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple47.84x16.02x6.26x
Price / SalesMarket cap ÷ Revenue43.19x2.82x0.53x0.91x0.58x
Price / BookPrice ÷ Book value/share0.10x14.40x0.95x0.79x0.56x
Price / FCFMarket cap ÷ FCF89.56x4.72x5.35x
TDOC leads this category, winning 3 of 5 comparable metrics.

Profitability & Efficiency

OPRX leads this category, winning 4 of 9 comparable metrics.

OPRX delivers a 5.5% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $-85 for NAKA. AMWL carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.34x. On the Piotroski fundamental quality scale (0–9), OPRX scores 7/9 vs NAKA's 2/9, reflecting strong financial health.

MetricNAKA logoNAKANakamoto Inc.HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…AMWL logoAMWLAmerican Well Cor…
ROE (TTM)Return on equity-84.8%-2.5%-12.4%+5.5%-33.5%
ROA (TTM)Return on assets-56.5%-0.6%-5.9%+4.0%-25.1%
ROICReturn on invested capital-42.1%+8.6%-11.5%+6.8%-95.1%
ROCEReturn on capital employed-76.2%+9.4%-10.0%+7.8%-36.6%
Piotroski ScoreFundamental quality 0–924676
Debt / EquityFinancial leverage0.41x2.34x0.75x0.20x0.02x
Net DebtTotal debt minus cash$187M$1.0B$259M$3M-$178M
Cash & Equiv.Liquid assets$23M$229M$781M$23M$182M
Total DebtShort + long-term debt$210M$1.3B$1.0B$26M$5M
Interest CoverageEBIT ÷ Interest expense-24.72x-8.76x2.84x-239.18x
OPRX leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

HIMS leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in HIMS five years ago would be worth $24,996 today (with dividends reinvested), compared to $325 for AMWL. Over the past 12 months, AMWL leads with a +25.4% total return vs NAKA's -99.3%. The 3-year compound annual growth rate (CAGR) favors HIMS at 50.8% vs NAKA's -66.6% — a key indicator of consistent wealth creation.

MetricNAKA logoNAKANakamoto Inc.HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…AMWL logoAMWLAmerican Well Cor…
YTD ReturnYear-to-date-72.3%-9.7%+5.8%-57.2%+79.2%
1-Year ReturnPast 12 months-99.3%-49.5%+6.3%-61.4%+25.4%
3-Year ReturnCumulative with dividends-96.3%+242.8%-70.4%-64.6%-81.4%
5-Year ReturnCumulative with dividends-96.3%+150.0%-95.1%-89.8%-96.7%
10-Year ReturnCumulative with dividends-96.3%+207.9%-42.8%+56.9%-98.1%
CAGR (3Y)Annualised 3-year return-66.6%+50.8%-33.4%-29.2%-42.9%
HIMS leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

AMWL leads this category, winning 2 of 2 comparable metrics.

AMWL is the less volatile stock with a 1.45 beta — it tends to amplify market swings less than NAKA's 2.88 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMWL currently trades 87.2% from its 52-week high vs NAKA's 0.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNAKA logoNAKANakamoto Inc.HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…AMWL logoAMWLAmerican Well Cor…
Beta (5Y)Sensitivity to S&P 5002.88x2.48x1.85x2.18x1.45x
52-Week HighHighest price in past year$679.20$70.43$9.77$22.25$9.96
52-Week LowLowest price in past year$0.38$13.74$4.40$4.57$3.71
% of 52W HighCurrent price vs 52-week peak+0.7%+42.8%+76.4%+23.9%+87.2%
RSI (14)Momentum oscillator 0–10035.451.559.046.162.3
Avg Volume (50D)Average daily shares traded274K24.7M4.4M442K78K
AMWL leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

OPRX leads this category, winning 1 of 1 comparable metric.

Analyst consensus: NAKA as "Buy", HIMS as "Hold", TDOC as "Hold", OPRX as "Buy", AMWL as "Hold". Consensus price targets imply 219.5% upside for OPRX (target: $17) vs -27.2% for AMWL (target: $6).

MetricNAKA logoNAKANakamoto Inc.HIMS logoHIMSHims & Hers Healt…TDOC logoTDOCTeladoc Health, I…OPRX logoOPRXOptimizeRx Corpor…AMWL logoAMWLAmerican Well Cor…
Analyst RatingConsensus buy/hold/sellBuyHoldHoldBuyHold
Price TargetConsensus 12-month target$8.00$27.00$7.40$17.00$6.33
# AnalystsCovering analysts220421515
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises01
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+0.4%+1.4%0.0%0.0%+0.0%
OPRX leads this category, winning 1 of 1 comparable metric.
Key Takeaway

OPRX leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TDOC leads in 1 (Valuation Metrics).

Best OverallOptimizeRx Corporation (OPRX)Leads 3 of 6 categories
Loading custom metrics...

NAKA vs HIMS vs TDOC vs OPRX vs AMWL: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is NAKA or HIMS or TDOC or OPRX or AMWL a better buy right now?

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -33. 0% for Nakamoto Inc. (NAKA). OptimizeRx Corporation (OPRX) offers the better valuation at 19. 7x trailing P/E (5. 6x forward), making it the more compelling value choice. Analysts rate Nakamoto Inc. (NAKA) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — NAKA or HIMS or TDOC or OPRX or AMWL?

On trailing P/E, OptimizeRx Corporation (OPRX) is the cheapest at 19.

7x versus Hims & Hers Health, Inc. at 59. 2x.

03

Which is the better long-term investment — NAKA or HIMS or TDOC or OPRX or AMWL?

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +150. 0%, compared to -96. 7% for American Well Corporation (AMWL). Over 10 years, the gap is even starker: HIMS returned +207. 9% versus AMWL's -98. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — NAKA or HIMS or TDOC or OPRX or AMWL?

By beta (market sensitivity over 5 years), American Well Corporation (AMWL) is the lower-risk stock at 1.

45β versus Nakamoto Inc. 's 2. 88β — meaning NAKA is approximately 98% more volatile than AMWL relative to the S&P 500. On balance sheet safety, American Well Corporation (AMWL) carries a lower debt/equity ratio of 2% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — NAKA or HIMS or TDOC or OPRX or AMWL?

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -33. 0% for Nakamoto Inc. (NAKA). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to -1452. 2% for Nakamoto Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — NAKA or HIMS or TDOC or OPRX or AMWL?

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -28. 7% for Nakamoto Inc. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OPRX leads at 11. 0% versus -108. 2% for NAKA. At the gross margin level — before operating expenses — HIMS leads at 73. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is NAKA or HIMS or TDOC or OPRX or AMWL more undervalued right now?

Analyst consensus price targets imply the most upside for OPRX: 219.

5% to $17. 00.

08

Which pays a better dividend — NAKA or HIMS or TDOC or OPRX or AMWL?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is NAKA or HIMS or TDOC or OPRX or AMWL better for a retirement portfolio?

For long-horizon retirement investors, American Well Corporation (AMWL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

Nakamoto Inc. (NAKA) carries a higher beta of 2. 88 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMWL: -98. 1%, NAKA: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between NAKA and HIMS and TDOC and OPRX and AMWL?

These companies operate in different sectors (NAKA (Financial Services) and HIMS (Healthcare) and TDOC (Healthcare) and OPRX (Healthcare) and AMWL (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NAKA is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; TDOC is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock; AMWL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.